Orforglipron
Orforglipron (Oral GLP-1 Receptor Agonist)
Investigational oral GLP-1 receptor agonist by Eli Lilly. Unlike injectable GLP-1s, orforglipron is a small molecule taken as a daily pill. Phase 3 trials show significant weight loss and metabolic improvements comparable to injectable alternatives.
📊 Evidence by Outcome
Significant weight loss
3 studies • Consistency: Moderate • Effect: Moderate
Improved glycemic control
3 studies • Consistency: Moderate • Effect: Moderate
Reduced appetite
3 studies • Consistency: Moderate • Effect: Moderate
No injection needed
3 studies • Consistency: Moderate • Effect: Moderate
Key Research
Peer-Reviewed Evidence • 1 Citations
Orforglipron Phase 2 Trial (ATTAIN)
••2023
Key Finding: Up to 14.7% body weight reduction at 36 weeks with the highest dose, comparable to injectable GLP-1 RAs
Citations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.
📋 Protocol Snapshot
Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.
Cost Guide
TBD (not yet approved)
Estimated UAE pricing. Costs vary by provider, dosage, and treatment plan.
Related Treatments
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, safety, accessibility, and value — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.